TTR and cardiomyopathy: Recent studies have shown that diflunisal treatment is associated with improved survival and the overall stability of clinical and functional cardiac biomarkers in patients with cardiomyopathy caused by wild‐type and variant TTR.42, 43 The present study further revealed that diflunisal can improve or stabilize the structural parameters of cardiomyopathy in ATTRv‐PN patients with cardiac involvement.